Tricyclic sulfones as RORγ modulators

US9815859B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jingwu Duan · Yardley, US
• T. G. Murali Dhar · Newtown, US
• David Marcoux · Pennington, US
• Qing Shi · Princeton, US
• Douglas G. Batt · Wilmington, US
• Qingjie Liu · Newtown, US
• Robert J. Cherney · Newark, US
• Lyndon A. M. Cornelius · Jackson, US
• Anurag S. Srivastava · Montgomery, US
• Myra Beaudoin Bertrand · Lambertville, US
• Carolyn A. Weigelt · Langhorne, US

Key dates

• Filing date: May 6, 2016
• Grant date: Nov 14, 2017
• Expiry date: May 6, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

There are described RORγ modulators of the formula (I),and formula (II)or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.